Early microscopic findings in preclinical inflammatory bowel disease
- PMID: 32601034
- DOI: 10.1016/j.dld.2020.05.052
Early microscopic findings in preclinical inflammatory bowel disease
Abstract
Background: The immune response involved in the pathogenesis of Inflammatory Bowel Disease (IBD) may be present years before the diagnosis, but the characteristics of the disease during the preclinical period have been scarcely investigated.
Aim: To describe the microscopic findings of preclinical IBD and its relationship with the natural history of the disease.
Methods: Medical records from all patients with an incidental diagnosis of IBD during a screening colonoscopy were included in this multicentric and retrospective study. We assessed 15 histologic items in the biopsy samples at diagnosis, and the Geboes score was calculated in patients with Ulcerative Colitis (UC). The main outcome was the development of gastrointestinal symptoms during follow-up.
Results: We included 110 patients (79 UC, 24 Crohn's Disease (CD) and 7 with unclassified disease). In UC the most common histologic findings were acute or chronic inflammatory infiltrate and crypt epithelial polymorphs, while in CD we observed acute or chronic neutrophilic infiltrate and epithelial irregularity. Granuloma were only observed in 4% of CD patients. Crypt distortion and the infiltration of neutrophils in the epithelium were associated with a higher risk of developing symptomatic disease.
Conclusions: Preclinical IBD shows specific microscopic findings and they are associated with the progression to symptomatic disease.
Keywords: Histology; Inflammatory bowel disease; Preclinical.
Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest IR-L has received financial support for travelling and educational activities from or has served as an advisory board member for MSD, Pfizer, Abbvie, Takeda, Janssen, Roche, Tillotts Pharma, Shire Pharmaceuticals, Ferring, Dr. Falk Pharma, Adacyte and Otsuka Pharmaceutical. MB-A has received financial support for travelling and educational activities from or has served as an advisory board member for Pfizer, MSD, Takeda, Abbvie, Kern, Janssen, Fresenius Kabi, Biogen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Chiesi, Gebro Pharma, Otsuka Pharmaceuticals, and Tillotts Pharma. The remaining authors declare no conflicts of interest related to this manuscript.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
